statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alltrna Announces Updates to Its Board of Directors

Alltrna Announces Updates to Its Board of Directors Alltrna Announces Updates to Its Board of Directors PR Newswire CAMBRIDGE, Mass., July 17, 2024 Chris Schade appointed as Board ChairpersonLynne...

Aprea Therapeutics files to sell 4.39M shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Wedbush Boosts Aprea Therapeutics (NASDAQ:APRE) Price Target to $11.00

Aprea Therapeutics (NASDAQ:APRE - Free Report) had its target price lifted by Wedbush from $9.00 to $11.00 in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has...

Brokers Set Expectations for Aprea Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:APRE)

Aprea Therapeutics, Inc. (NASDAQ:APRE  Free Report)  Equities researchers at Wedbush reduced their Q1 2024 EPS estimates for shares of Aprea Therapeutics in a research report issued on...

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly...

Buy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE Research Report), with a price target of $20.00...

Aprea Therapeutics: Q4 Earnings Insights

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Bernd R. Seizinger Purchases 6,860 Shares

Aprea Therapeutics, Inc. (NASDAQ:APRE  Get Free Report) Director Bernd R. Seizinger acquired 6,860 shares of the firms stock in a transaction on Wednesday, March 13th. The stock was...

Aprea Therapeutics enters private placement financing for up to $34M

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an...

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Volume	3,756.00
52-Wk High	$8.85
52-Wk Low	$2.91

APRE Aprea Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals